Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,237 people get ALXA articles and Market Currents by email alert.
Get email alerts on ALXA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
Alexza Pharmaceuticals Inc. - Special CallWed, May 8
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 22, 2013)
-
-
-
-
PR Newswire (Mar 26, 2013)
-
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 6, 2013)
-
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 21, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alexza Pharmaceuticals: Forward Looking Approval Catalyst In PlayM. E. Garza • Wed, Dec 14, 2011 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Using Options To Benefit From The Binary Nature Of FDA DecisionsDavid Anber • Thu, Oct 18, 2012 -
-
-
-
4 Healthcare Stocks Breaking Out Mid-WeekTimeless Wealth • Thu, May 3, 2012 -
-
-
Alexza Pharmaceuticals Inc. - Special CallWed, May 8
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call TranscriptMon, Nov 9, 2009
-
Alexza Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptTue, Mar 10, 2009
-
Alexza Pharmaceuticals, Inc. Q3 2008 Earnings Call TranscriptTue, Nov 18, 2008
-
Alexza Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Alexza Pharmaceuticals, Inc. Q1 2008 Earnings Call TranscriptMon, May 12, 2008
-
Alexza Pharmaceuticals, Inc.Q4 2007 Earnings Call TranscriptMon, Mar 17, 2008
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 8, 2013)
-
PR Newswire (May 1, 2013)
-
PR Newswire (Apr 22, 2013)
-
PR Newswire (Mar 26, 2013)
-
PR Newswire (Mar 13, 2013)
-
PR Newswire (Mar 6, 2013)
-
PR Newswire (Feb 25, 2013)
-
PR Newswire (Feb 21, 2013)
-
PR Newswire (Jan 3, 2013)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 24, 2012)
-
at MarketWatch.com (Dec 21, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 18, 2012)
-
PR Newswire (Oct 17, 2012)
ALXA vs. ETF Alternatives
Company Description
We are a pharmaceutical company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system, or CNS, conditions. All of our product candidates are based on our proprietary technology, the Staccato system. The... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, May 15, 6:32 AM Alexza Pharmaceuticals (ALXA): Q1 EPS of -$1.31 misses by $0.86. Revenue of $729K beats by $271M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Wednesday, May 8, 12:53 PM
Midday top 10 gainers: TRMD +68%. SYNM +35%. AFFY +35%. ALXA +25%. CSPI +21%. PSE +21%. NBG +20%. WBMD +18%. SCOK +17%. EA +16%.
Midday top 10 losers: FIO -25%. OCLR -23%. LIOX -18%. VCLK -17%. AXLL -16%. OCLS -15%. BTH -15%. SALM -13%. ACFC -12%. SNTA -12%. Comment! [On the Move] -
Wednesday, May 8, 9:17 AM
Premarket gainers: ALXA +51%. PSE +19%. LEDR +16%. NBG +11%. WFM +8%. EA +6%. PRTS +6%. SFUN +6%. CTSH +5%.
Losers: FIO -22%. VCLK -19%. OCLR -19%. AXLL -9%. CIE -7%. CHRW -7%. SODA -6%. DDD -6%. SYMC -5%. Z -5%. VVUS -5%. Comment! [On the Move] - Wednesday, May 8, 9:11 AM Alexza Pharmaceuticals (ALXA) comes off trading halt, now up 52% premarket following the license deal with Teva (TEVA +0.3% premarket). The conference call discussing the matter is underway. 3 Comments [Breaking News, Healthcare, On the Move]
- Wednesday, May 8, 9:00 AM Alexza Pharmaceuticals (ALXA) announces an exclusive U.S. license deal for Adasuve with Teva Pharmaceutical (TEVA). Nice deal for Alexza - it will receive an upfront payment of $40M with eligibility for another $195M based on milestones. Conference call to discuss is about to begin. Shares remains halted. (PR) Comment! [Healthcare, Breaking News]
- Wednesday, May 8, 8:31 AM Alexza Pharmaceuticals (ALXA) is halted from trading with news pending. Comment! [Breaking News, Healthcare]
- Wednesday, April 3, 11:03 AM Alexza Pharmaceuticals (ALXA +4%) gives back a little but remains firmly in the green following a +7% run-up during the pre-open session on an earlier upgrade from Piper Jaffray to Overweight. Piper notes that it's channel checks with ER physicians, psychiatrists, and opinion leaders was even more encouraging than it expected on both the near and longer-term market potential for Adasuve versus previous projections. Additionally, it's clinical attributes bode well for a value-added partnership being signed soon to enable effective launch in Q3. 1 Comment [Healthcare, On the Move]
- Wednesday, April 3, 9:25 AM Alexza Pharmaceuticals (ALXA) is trading higher before the bell after Piper Jaffray upgrades the stock to Overweight from Neutral. Shares +7.3% premarket. 1 Comment [Healthcare]
-
Wednesday, April 3, 9:10 AM
Premarket gainers: CALL +14%. CONN +10%. ZNGA +10%. ASTX +10%. UNXL +9%. AWRE +9%. OMPI +9%. NVAX +9%. ALXA +8%. MHR +7%. NFX +6%.
Losers: MSPD -19%. GPN -7%. 3 Comments [On the Move] - Tuesday, March 26, 5:44 PM More on Alexza Pharmaceuticals (ALXA): Q4 EPS misses expectations, with revenues coming at $729K, well below estimates of $3.48M. In the same period last year, the company reported a loss per share of $1.34 on revenues of $1.88M. R&D expenses were lower for the quarter, largely as a result of the suspension of development of AZ-007 and Staccato nicotine product candidates starting in late 2011, as well as efforts to conserve cash. Comment! [Healthcare, Earnings]
- Tuesday, March 26, 5:15 PM Alexza Pharmaceuticals (ALXA): Q4 EPS of -$0.65. Revenue of $729K. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
- Thursday, February 21, 9:41 AM The EU approves Alexza Pharmaceuticals' (ALXA +2.2%) Adasuve, a treatment for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. The authorization adds to FDA backing. Alexza plans to launch Adasuve in the U.S. and EU in Q3. (PR) 1 Comment [Healthcare]
-
Thursday, February 21, 9:10 AM
Premarket gainers: PRKR +38%. RPRX +31%. NVGN +28%. BRY +22%. PEGA +17%. LOCK +7%. LNCO +5%. ALXA +5%.
Losers: GENT -37%. PAY -34%. GFI -17%. ALU -7%. WLT -6%. TSLA -5%. Comment! [On the Move] -
Monday, December 24, 2012, 2:57 PM
After-hours top gainers, as of 2:30 p.m.: TVIX +3.6%. UVXY +3.1%. VXX +1.9%. SE +1.6%. ALXA +1.6%.
After-hours top losers: UGAZ -2.1%. XIV -1.7%. SVXY -1.7%. AIG -1.6%. ABB -1.3%. Comment! [On the Move] -
Monday, December 24, 2012, 11:15 AM
Midday top 10 gainers: ATV +34%. CT +18%. ALIM +12%. CLSN +12%. EJ +11%. EDAP +11%. GSS +11%. RGLS +10%. AVEO +10%. EGLE +10%.
Top 10 Losers: MHH -30%. TLAB -27%. ALXA -14%. XRTX -12%. AMPL -11%. CIG -10%. SVA -9%. ISS -9%. MITL -8%. RPTP -8%. 1 Comment [On the Move] - Monday, December 24, 2012, 9:10 AM Premarket Losers: TLAB -26%. ALXA -11%. Comment! [On the Move]
-
Ryan Mallory
Fuinhaz Setups for May 15 2013 | $ACAD $ALXA $CETV $CSIQ $SCTY $SODA $SPU | SharePlanner http://bit.ly/13xbTQb - View all 0 replies
-
- View all 0 replies
-
- View all 3 replies
-
Perkins Cove: Ohhh...yah.....up 45% to $6.30+ ....congrats ALXA holders. Anybody here get that nice jump?
-
-
- View all 0 replies
-
Jason F
Nothing Bullish About $ALXA stock chart. Really bearish chart. http://bit.ly/WOKzrE (analysis in the link) - View all 0 replies
-
- View all 1 replies
-
-
emeickhoff
I think its halted to prevent the short sellers to destroy the price on approval. This is a good sign $ALXA - View all 1 replies
-
-
- View all 0 replies
-
Jason F
My $ALXA Run Down Targets -Chart Analysis - http://bit.ly/XWgkhe (On the site I posted a chart saying yesterday was time to sell) - View all 1 replies
-
Jason F: I think on one of the articles or stocktalks yesterday I wrote time to sell ALXA. The TA on the chart provided warning signs.
-
- View all 13 replies
-
-
LATEST REPLIES
-
- View all 3 replies
-
Perkins Cove: Ohhh...yah.....up 45% to $6.30+ ....congrats ALXA holders. Anybody here get that nice jump?
-
-
- View all 13 replies
-
-
-
- View all 5 replies
-
Scott Matusow: Zacks analyst wrote a negative piece which I find to be partly disingenuous.
-
u681694: Scott - what's your opinion on where ALXA is heading over the short - medium term?
-
- View all 1 replies
-
-
emeickhoff
I think its halted to prevent the short sellers to destroy the price on approval. This is a good sign $ALXA - View all 1 replies
-
-
- View all 6 replies
-
medic11: Same s@#t, different pile. Stock is down post approval. Just like AMRN.
-
JMEaramn: Any ballparks as to how the restrictions are going to affect the stock price?
-
Jason F
My $ALXA Run Down Targets -Chart Analysis - http://bit.ly/XWgkhe (On the site I posted a chart saying yesterday was time to sell) - View all 1 replies
-
Jason F: I think on one of the articles or stocktalks yesterday I wrote time to sell ALXA. The TA on the chart provided warning signs.
-
- View all 3 replies
-
foldholder: why is the stock moving down today? how higher will it reach by 21st?
-
JMattius: No FDA news until Friday so I expect a bit of a slow bleed leading up to Friday. Weak hands may be selling as well.
-
reachmygoals1
$ALXA has chances to go 2 for 2 this month-Eu decision & FDA decision.Last month, manufacturing facility was inspected and satisfactory. - View all 3 replies
-
foldholder: $ALXA has a new article http://seekingalpha.com/a/mohd. Does it still make sense to buy this stock?
-
JMattius: Buy if you feel it will get approved. Sell or stay away if you don't. No article can predict what the FDA is going to do.
-
- View all 3 replies
-
freefdawatchlist: don't buy more, because if fda delay it by 3 month, the stock may drop. Check out other stock which haven't rallied up till now.
-
